Gene therapy by electroporation for the treatment of chronic renal failure in companion animals

BMC Biotechnology

Volumn 9, Issue , 2009, Pages

  Brown, Patricia A ^a   Bodles Brakhop, Angela M ^b   Pope, Melissa A ^b   Draghia Akli, Ruxandra ^b  

^a VGX Animal Health Inc   (United States)

^b VGX Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD UREAS; BODY WEIGHTS; CHRONIC RENAL FAILURES; ELECTROPORATION; GENE THERAPIES; GROWTH HORMONE-RELEASING HORMONES; INSULIN-LIKE GROWTH FACTOR I; KIDNEY FUNCTIONS; POST TREATMENTS; PROTEIN METABOLISMS; QUALITY OF LIVES; RENAL FUNCTIONS; TOLERANCE LEVELS;

ANIMAL CELL CULTURE; BIOCHEMISTRY; DRUG PRODUCTS; GENETIC ENGINEERING; METABOLISM; UREA;

ANIMALS;

CREATININE; GROWTH HORMONE RELEASING FACTOR; NITROGEN; PLASMID VECTOR; SOMATOMEDIN C; UREA; IRON; PROTEIN;

ARTICLE; BIOSYNTHESIS; BODY WEIGHT; CAT; CATABOLISM; CHRONIC DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOG; DRUG EFFICACY; DRUG RESPONSE; ELECTROPORATION; EXERCISE TOLERANCE; GENE THERAPY; HEMATOLOGICAL PARAMETERS; INCREASED APPETITE; KIDNEY FAILURE; NONHUMAN; PHYSICAL ACTIVITY; PROTEIN METABOLISM; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THINKING; UREA NITROGEN BLOOD LEVEL; AGING; ANIMAL; ANIMAL DISEASE; BLOOD; CHRONIC KIDNEY FAILURE; GENETICS; METABOLISM; PLASMID;

ANIMALIA; CANIS FAMILIARIS;

AGING; ANIMALS; BLOOD UREA NITROGEN; BODY WEIGHT; CATS; CREATININE; DOGS; ELECTROPORATION; GENE THERAPY; GROWTH HORMONE-RELEASING HORMONE; INSULIN-LIKE GROWTH FACTOR I; IRON; KIDNEY FAILURE, CHRONIC; PLASMIDS; PROTEINS;

EID: 63849191342     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-9-4     Document Type: Article

References (50)

1. Al Suwaidi J Reddan DN Williams K Pieper KS Harrington RA Califf RM et al Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes Circulation 2002, 106:974-980 10.1161/01.CIR.0000027560.41358.B3 12186803
2. Nampoory MR Johny KV Costandi JN Gupta RK Nair MP Samhan M et al Inferior long-term outcome of renal transplantation in patients with diabetes mellitus Med Princ Pract 2002, 11:29-34 10.1159/000048657 12116692
3. Weiner DE Causes and consequences of chronic kidney disease: implications for managed health care J Manag Care Pharm 2007, 13:S1-S9 17402808
4. Crook ED Washington DO Flack JM Screening and prevention of chronic kidney disease J Natl Med Assoc 2002, 94:55S-62S 2594167 12152913
5. Mak RH Cheung WW Roberts CT Jr The growth hormone-insulin-like growth factor-I axis in chronic kidney disease Growth Horm IGF Res 2007, 18:17-25 10.1016/j.ghir.2007.07.009 17826224
6. Mahesh S Kaskel F Growth hormone axis in chronic kidney disease Pediatr Nephrol 2007, 23:41-48 2100434 17676425 10.1007/s00467-007-0527-x
7. Clark RG Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure Pediatr Nephrol 2005, 20:290-294 10.1007/ s00467-004-1714-7 15682316
8. Seikaly MG Salhab N Warady BA Stablein D Use of rhGH in children with chronic kidney disease: Lessons from NAPRTCS Pediatr Nephrol 2007, 22:1195-1204 10.1007/s00467-007-0497-z 17530299
9. Wuhl E Schaefer F Effects of growth hormone in patients with chronic renal failure: Experience in children and adults Horm Res 2002, 58(Suppl 3):35-38 12435895
10. Tone CM Cardoza DM Carpenter RH Draghia-Akli R Long-term effects of plasmid-mediated growth hormone releasing hormone in dogs Cancer Gene Ther 2004, 11:389-396 10.1038/sj.cgt.7700717 15073611
11. Brown PA Davis WC Draghia-Akli R Immune enhancing effects of growth hormone releasing hormone delivered by plasmid injection and electroporation Molecular Therapy 2004, 10:644-651 10.1016/ j.ymthe.2004.06.1015 15451448
12. Brown PA Bodles-Brakhop A Draghia-Akli R Plasmid growth hormone releasing hormone therapy in healthy and laminitis-afflicted horses-evaluation and pilot study J Gene Med 2008, 10:564-574 10.1002/ jgm.1170 18302303
13. Bodles-Brakhop AM Brown PA Pope MA Draghia-Akli R Double-blinded, Placebo-controlled Plasmid GHRH Trial for Cancer-associated Anemia in Dogs Mol Ther 2008, 16:862-870 10.1038/mt.2008.31 18388931
14. Scheerlinck JP Karlis J Tjelle TE Presidente PJ Mathiesen I Newton SE In vivo electroporation improves immune responses to DNA vaccination in sheep Vaccine 2004, 22:1820-1825 10.1016/j.vaccine.2003.09.053 15068866
15. Tjelle TE Salte R Mathiesen I Kjeken R A novel electroporation device for gene delivery in large animals and humans Vaccine 2006, 24:4667-4670 10.1016/j.vaccine.2005.08.068 16162367
16. van Drunen Littel-van den Hurk Luxembourg A Ellefsen B Wilson D Ubach A Hannaman D et al Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle Vaccine 2008, 26:5503-5509 10.1016/j.vaccine.2008.07.093 18708108
17. Bergman PJ McKnight J Novosad A Charney S Farrelly J Craft D et al Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial Clin Cancer Res 2003, 9:1284-1290 12684396
18. Kopyt N Management and treatment of chronic kidney disease Nurse Pract 2007, 32:14-23 10.1097/01.NPR.0000294223.14054.04 18084856
19. O'Sullivan AJ Lawson JA Chan M Kelly JJ Body composition and energy metabolism in chronic renal insufficiency Am J Kidney Dis 2002, 39:369-375 10.1053/ajkd.2002.30558 11840379
20. Robinson B Artz AS Culleton B Critchlow C Sciarra A Audhya P Prevalence of anemia in the nursing home: Contribution of chronic kidney disease J Am Geriatr Soc 2007, 55:1566-1570 10.1111/j.1532-5415.2007.01389.x 17727646
21. Rubin SI Chronic renal failure and its management and nephrolithiasis Vet Clin North Am Small Anim Pract 1997, 27:1331-1354 9348633
22. Levin A Identification of patients and risk factors in chronic kidney disease - evaluating risk factors and therapeutic strategies Nephrol Dial Transplant 2001, 16(Suppl 7):57-60 11590259
23. Elliott DA Nutritional management of chronic renal disease in dogs and cats Vet Clin North Am Small Anim Pract 2006, 36:1377-84 10.1016/ j.cvsm.2006.08.011 17085241
24. Khorram O Yeung M Vu L Yen SS Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women J Clin Endocrinol Metab 1997, 82:3590-3596 10.1210/jc.82.11.3590 9360512
25. Bergamaschi S Giavoli C Ferrante E Lania A Rusconi R Spada A et al Growth hormone replacement therapy in growth hormone deficient children and adults: Effects on hemochrome J Endocrinol Invest 2006, 29:399-404 16794362
26. Deicher R Horl WH Hormonal adjuvants for the treatment of renal anaemia Eur J Clin Invest 2005, 35(Suppl 3):75-84 10.1111/ j.1365-2362.2005.01533.x 16281962
27. Randolph JE Scarlett J Stokol T MacLeod JN Clinical efficacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia J Vet Intern Med 2004, 18:81-91 10.1892/ 0891-6640(2004)18<81:CEASOR>2.0.CO;2 14765736
28. Randolph JE Scarlett JM Stokol T Saunders KM MacLeod JN Expression, bioactivity, and clinical assessment of recombinant feline erythropoietin Am J Vet Res 2004, 65:1355-1366 10.2460/ajvr.2004.65.1355 15524322
29. Gotloib L Silverberg D Fudin R Shostak A Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron J Nephrol 2006, 19:161-167 16736414
30. Horl WH Iron therapy for renal anemia: How much needed, how much harmful? Pediatr Nephrol 2007, 22:480-489 1805051 17206511 10.1007/ s00467-006-0405-y
31. Brearley C Priestley A Leighton-Scott J Christen M Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle BMC Clin Pharmacol 2007, 7:10 2093927 17922895 10.1186/1472-6904-7-10
32. Prud'homme GJ Glinka Y Khan AS Draghia-Akli R Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases Curr Gene Ther 2006, 6:243-273 10.2174/ 156652306776359504 16611045
33. Luxembourg A Evans CF Hannaman D Electroporation-based DNA immunisation: translation to the clinic Expert Opin Biol Ther 2007, 7:1647-1664 10.1517/14712598.7.11.1647 17961089
34. Miyazaki S Miyazaki J In vivo DNA electrotransfer into muscle Dev Growth Differ 2008, 50:479-483 10.1111/j.1440-169X.2008.01025.x 18445065
35. Aihara H Miyazaki J Gene transfer into muscle by electroporation in vivo Nat Biotechnol 1998, 16:867-870 10.1038/nbt0998-867 9743122
36. Cemazar M Golzio M Sersa G Rols MP Teissie J Electrically-assisted nucleic acids delivery to tissues in vivo: Where do we stand? Curr Pharm Des 2006, 12:3817-3825 10.2174/138161206778559740 17073680
37. Roos AK Moreno S Leder C Pavlenko M King A Pisa P Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation Mol Ther 2006, 13:320-327 10.1016/j.ymthe.2005.08.005 16185933
38. Khan AS Fiorotto ML Cummings KK Pope MA Brown PA Draghia-Akli R Maternal GHRH plasmid administration changes pituitary cell lineage and improves progeny growth of pigs Am J Physiol Endocrinol Metab 2003, 285:E224-E231 12670834
39. Bodles-Brakhop AM Draghia-Akli R DNA vaccination and gene therapy: optimization and delivery for cancer therapy Expert Rev Vaccines 2008, 7:1085-1101 10.1586/14760584.7.7.1085 18767956
40. Rice J Ottensmeier CH Stevenson FK DNA vaccines: Precision tools for activating effective immunity against cancer Nat Rev Cancer 2008, 8:108-120 10.1038/nrc2326 18219306
41. Kutzler MA Weiner DB DNA vaccines: Ready for prime time? Nat Rev Genet 2008, 9:776-788 10.1038/nrg2432 18781156
42. Ng T Marx G Littlewood T Macdougall I Recombinant erythropoietin in clinical practice Postgrad Med J 2003, 79:367-376 1742767 12897214 10.1136/pmj.79.933.367
43. Lu X Zhou A Jin C [The effects of electroporation-mediated erythropoietin (EPO) gene transfer into skeleton muscle on renal anemia] Zhonghua Yi Xue Za Zhi 2000, 80:222-225 11798762
44. Ataka K Maruyama H Neichi T Miyazaki J Gejyo F Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure Am J Nephrol 2003, 23:315-323 10.1159/000072913 12915775
45. Fattori E Cappelletti M Zampaglione I Mennuni C Calvaruso F Arcuri M et al Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates J Gene Med 2005, 7:228-236 10.1002/jgm.652 15515133
46. Gao G Lebherz C Weiner DJ Grant R Calcedo R McCullough B et al Erythropoietin gene therapy leads to autoimmune anemia in macaques Blood 2004, 103:3300-3302 10.1182/blood-2003-11-3852 14695227
47. Draghia-Akli R Ellis KM Hill LA Malone PB Fiorotto ML High-efficiency growth hormone releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs FASEB J 2003, 17:526-528 12514110
48. Li X Eastman EM Schwartz RJ Draghia-Akli R Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences Nat Biotechnol 1999, 17:241-245 10.1038/6981 10096290
49. Khan AS Brown PA Draghia-Akli R Plasmid-based growth hormone releasing hormone supplementation and its applications Current Opinion in Molecular Therapeutics 2005, 7:306-316 16121696
50. Khan AS Smith LC Abruzzese RV Cummings KK Pope MA Brown PA et al Optimization of electroporation parameters for the intramuscular delivery of plasmids in pigs DNA Cell Biol 2003, 22:807-814 10.1089/ 104454903322625019 14683591